Postoperative adjuvant tyrosine kinase inhibitors combined with anti-PD-1 antibodies improves surgical outcomes for hepatocellular carcinoma with high-risk recurrent factors
- Resource Type
- Source
- Frontiers in Immunology. 14
- Subject
Immunology Immunology and Allergy - Language
- English
- ISSN
- 1664-3224